No Data
No Data
BioXcel Therapeutics Cut to Underperform From Buy by B of A Securities
BofA Securities Downgrades BioXcel Therapeutics(BTAI.US) to Sell Rating, Announces Target Price $0.25
Canaccord Genuity Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $5
BioXcel Therapeutics Analyst Ratings
Bioxcel Therapeutics: Strategic Initiatives and Market Opportunities Drive Buy Rating Amid Financial Challenges
BioXcel Therapeutics (BTAI) Moves to Buy: Rationale Behind the Upgrade